dihexa hgf c-met agonist Artificial human Met agonists based on macrocycle scaffolds Targeting HGF/c-MET signaling to regulate

The potential of TB-500 on angiogenesis and migration was assessed using MTT assays for cell viability, tube formation assays for angiogenesis, and wound healing assays for the migratory ability of HUVEC

Biochemical and Biophysical Research Communications

The clinical drug development program was halted in 2007 after the pivotal Phase IIb trial did not show statistically significant weight loss in the primary endpoint

Important safety warnings seek urgent medical attention if you experience: Severe or persistent abdominal pain, which may radiate to the back this could indicate pancreatitis , a serious but rare risk associated with GLP-1based therapies as a class [16] [17] Right upper quadrant pain, fever, or jaundice these may suggest gallbladder disease , another class-associated risk Signs of dehydration (dizziness, reduced urine output, extreme thirst) resulting from severe vomiting or diarrhoea, which can affect kidney function Pregnancy and breastfeeding: Use of GLP-1based therapies and related investigational agents is not recommended during pregnancy or breastfeeding